CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| 10358 | ETCTN | Phase 1/1B study of DS-8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial) | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10355 | ETCTN | A phase I study of DS-8201a in combination with olaparib in HER2-expressing malignancies | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10349 | ETCTN | A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas | Adult CIRB - Early Phase Emphasis | Completed |
| 10347 | ETCTN | A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS) | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10346 | ETCTN | Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10335 | ETCTN | A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10334 | ETCTN | BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) who are Ineligible or who Refuse Intensive Chemotherapy | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10330 | ETCTN | A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10329 | ETCTN | Phase I Sequential Trial of Agents Against DNA Repair (STAR) | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10327 | ETCTN | A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients | Adult CIRB - Early Phase Emphasis | Available to Open |